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	 Baseline	 Post-Exercise	 	
	 Mean	±	SD	 Mean	±	SD	 p	value	
RER	 0.95	±	0.04	 0.89	±	0.03	 <0.001	
Palmitate	Oxidation,	ex	vivo	
(nmol/hr/mg	protein)	 615.9	±	375.9	 887.3	±	404.3	 0.01	
Total	IMCL	Content	(AU)	 27.7	±	27.5	 21.3	±	19.4	 0.21	
IMCL	Content	in	type	1	fibers	(AU)	 29.3	±	28.6	 23.4	±	22.6	 0.21	
IMCL	Content	in	type	2	fibers	(AU)	 25.9	±	25.9	 20.1	±	17.9	 0.25	
IMCL	Fiber	type	1	density	(AU)	 11.2	±	13.6	 7.9	±	7.5	 0.24	
IMCL	Fiber	type	2	density	(AU)	 16.3	±	16.9	 13.3	±	13.3	 0.40	
Glycogen	Content	(AU)	 8.40	±	0.79	 7.32	±	0.68	 0.001	
FFA	(mmol/L)	 0.45	±	0.17	 0.73	±	0.30	 <0.001	
Epinephrine	(mg/dL)	 46.9	±	17.8	 193.4	±	77.5	 <0.001	





















































































































































































































































































































































































































































































		 Active	 Lean,	Sedentary	 Type	2	Diabetics	 	
		 Mean	±	SD	 Mean	±	SD	 Mean	±	SD	 p	value	
		 		 		 		 		
N	 4	 5	 4	 --	
Weight	(kg)	 79.98	±	8.88b	 76.50	±	8.19b	 110.53	±	18.31a,c	 0.005	
FM	(kg)	 10.58	±	1.96b	 14.36	±	6.29b	 31.41	±	2.89a,c	 <0.001	
FFM	(kg)	 69.75	±	7.50	 62.14	±	4.30	 64.73	±	5.37	 0.18	
%	Fat	 13.15	±	1.95b	 18.36	±	6.39b	 35.27	±	5.37a,c	 <0.001	
BMI	 25.12	±	2.55b	 24.18	±	0.55b	 39.65	±	6.98a,c	 <0.001	
Serum	Glucose	(mg/dL)	 88.75	±	2.75b	 87.80	±	5.50b	 117.25a,c	 0.02	
GDR	(mg/min/EMBS)	 12.39	±	2.29b	 11.16	±	3.01b	 1.26	±	0.56a,c	 <0.001	
Maximal	ATP	production	
(mM/min)	 1.17	±	0.07a,b	 0.66	±	0.11c	 0.59	±	0.24c	 <0.001	
Basal	ATP	production	(μM/min)	 7.27	±	2.18b	 5.35	±	1.42	 3.37	±	1.81c	 0.04	


















































































































































































































































































































































































































		 Control	 		 Pre-Exercise	 Post-Exercise	 		 P	value	 P	value	
Age	(yr)	 29.7	±	12.4	 		 27.0	±2.9	 --	 		 0.65	 --	
Weight	(kg)	 78.9	±	15.7	 		 82.2	±	18.2	 81.4	±21.6	 		 0.74	 0.69	
BMI	(kg/m2)	 26.5	±	5.4	 		 30.8	±	4.2	 30.4	±	5.8	 		 0.17	 0.66	
Total	body	fat	(%)	 29.9	±	9.8	 		 36.8	±	5.0	 34.8	±	6.1	 		 0.19	 0.21	
FM	(kg)	 23.3	±9.3	 		 30.8	±	11.1	 29.3	±	13	 		 0.23	 0.39	
FFM	(kg)	 55.6	±	15.9	 		 51.4	±	7.9	 52.1	±	9.0	 		 0.60	 0.24	
Visceral	AT	(kg)	 1.4	±	0.8	 		 1.2	±	0.5	 1.1	±	0.7	 		 0.75	 0.64	
Subcutaneous	AT	(kg)	 11.4	±	1.8	 		 10.9	±	4.8	 10.5	±	5.7	 		 0.86	 0.47	
IHL	(AU)	 0.013	±	0.017	 		 0.13	±	0.17	 0.03	±	0.05	 		 0.16	 0.20	
IMCL	(soleus,	AU)	 0.006	±	0.003	 		 0.006	±	0.004	 0.007	±	0.005	 		 0.89	 0.27	
Glucose,	fasting	(mg/dL)	 103.5	±	28.6	 		 82.2	±	6.3	 89.6	±	5.5	 		 0.14	 0.08	
Insulin,	fasting	(mg/dL)	 11.0	±	10.2	 		 9.8	±	3.9	 12.4	±	5.6	 		 0.81	 0.51	
HOMA-IR	(AU)	 3.4	±	4.2	 		 2.0	±	0.8	 2.7	±	1.2	 		 0.50	 0.42	
GDR/EMBS	(mg/kgFFM	
+17.7)	 6.8	±	4.3	 		 6.3	±	1.2	 7.6	±	1.6	 		 0.79	 0.02	
Resting	Metabolic	
Rate/FFM	(kcal/day/kg)	 30.3	±	4.8	 		 30.7	±	5.0	 30.0	±	2.7	 		 0.91	 0.62	
Resting	RQ	 0.80	±	0.03	 		 0.81	±	0.02	 0.80	±	0.01	 		 0.37	 0.21	
Clamp	RQ	 0.93	±	0.07	 		 0.90	±	0.04	 0.90	±	0.05	 		 0.50	 0.83	
ΔRQ	(Clamp	vs	Resting)	 0.13	±	0.07	 		 0.09	±	0.02	 0.10	±	0.03	 		 0.26	 0.72	
VO2max	(mL/min/kg)	 27.7	±	10.0	 		 29.5	±	3.0	 33.6	±	4.3	 		 0.71	 0.04	
Fat	Cell	Size	(nL)	 0.69	±	0.31	 		 0.68	±	0.13	 0.76	±	0.25	 		 0.92	 0.40	
Testosterone	(ng/dL)	 35.4	±	11.7	 		 92.4	±	41.2	 64.8	±	25.3	 		 0.002	 0.61	
SHBG	(nmol/L)	 24.1	±	4.6	 		 30.9	±	31.7	 34.2	±	19.3	 		 0.56	 0.75	
FAI	(AU)	 5.1	±	1.4	 		 18.8	±	14.2	 13.9	±	17.5	 		 0.02	 0.67	
Number	of	ovarian	cysts				
(2-9mm	in	diameter)a	
29.4	±	46.1	
	 	
97	±	29.7	
	
119.4	±	28.6		
	 	
0.008	
	
0.10	
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Women	with	PCOS	did	however	differ	significantly	from	controls	in	terms	of	subcutaneous	
adipose	tissue	gene	expression	for	candidates	responsible	for	lipolysis,	lipid	droplet	perilipin	
proteins,	and	coatomer	proteins.	As	shown	in	Figure	4.1A,	perilipin	1,	3,	and	5	(PLIN1,	PLIN3,	
and	PLIN5,	respectively)	were	~80-90%	lower	in	women	with	PCOS	when	compared	to	controls,	
while	perilipin	2	(PLIN2)	and	perilipin	4	(PLIN4)	were	approximately	3-fold	higher.	Expression	
mRNA	levels	of	coatomer	GTPases	ARF1,	ARFRP1,	and	βCOP	(Figure	4.1B)	were	~80%	lower	in	
women	with	PCOS	compared	to	controls,	with	GBF1	and	Sec23a	being	expressed	~9-	and	7-fold	
higher,	respectively.	Finally,	lipase	mRNA	expression	of	ATGL	and	monoglycerol	lipase	(MGL)	
were	reduced	by	90%	and	65%	respectively,	with	no	difference	in	the	expression	of	CGI-58	
(Figure	4.1C).	
	
Figure	4.1:	Gene	expression	from	abdominal	subcutaneous	adipose	tissue	from	women	with	
PCOS	verses	age,	BMI,	and	percent	fat	matched	controls	(cross-sectional	study).	A)	Perilipin	
family	of	protein	gene	expression	of	all	five	perilipin	proteins	shows	drastic	differences	in	
expression.	Perilipin	1	(PLIN1),	perilipin	3	(PLIN3),	and	perilipin	5	(PLIN5)	are	all	expressed	
approximately	90%	lower	in	females	with	PCOS	compared	to	controls.	Perilipin	2	(PLIN2)	and	
perilipin	4	(PLIN4)	are	expressed	about	3	times	higher	when	compared	to	controls.	B)	Coatomer	
proteins	involved	in	ER-to-Golgi	transport	were	also	differentially	regulated	on	the	gene	
expression	level.	ADP-ribosylation	Factor	1	(ARF1),	ARF	related	protein	1	(ARFRP1),	and	Beta-
coatomer	(βCOP,	part	of	the	COPI	complex)	were	drastically	reduced	in	women	with	PCOS.	
GDP-exchange	Brefeldin	A	resistant	Factor	1	(GBF1,	which	operated	in	conjunction	with	ARF1)	
and	Sec23a	(part	of	the	COPII	complex)	were	both	expressed	approximately	8fold	higher	in	the	
women	with	PCOS.	C)	Expression	of	Adipose	Triglyceride	Lipase	(ATGL)	and	Monoglyceride	
Lipase	(MGL)	were	both	reduced	in	women	with	PCOS	on	the	gene	expression	level,	while	there	
was	no	statistical	difference	in	the	expression	of	the	ATGL	co-activator	CGI-58.	*p	<	0.05;	**p	<	
0.01;	***p	<	0.001	
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4.3.2	Effect	of	Sixteen-Weeks	of	Aerobic	Exercise	Training	in	Women	with	PCOS	
Aerobic	exercise	resulted	in	a	~10%	improvement	in	maximal	aerobic	capacity	(VO2Max,	
p=0.04)	and	a	~20%	improvement	in	glucose	disposal	rate	(p=0.02)	(Table	4.1).	No	other	
changes	were	noted	in	terms	of	body	composition,	abdominal	adipose	depot	size	(visceral	or	
subcutaneous	depots),	ectopic	lipid	accumulation	(in	the	liver	or	muscle),	or	in	fat	cell	size	
(Table	4.1).	However,	alterations	were	seen	in	the	gene	expression	in	the	adipose	tissue	
following	exercise.	Of	all	the	measured	perilipins,	only	expression	of	PLIN3	increased	
significantly	(p<0.05;	Figure	4.2A),	whereas	PLIN1,	PLIN2,	PLIN4	and	PLIN5	did	not	change.	On	
average,	ARF1,	ARFRP1,	βCOP,	and	Sec23a	expressions	were	increased	by	approximately	5-,	8-,	
7-,	and	4-	fold,	respectively	(p<0.05),	with	no	changes	in	GBF1	(Figure	4.2B).	Additionally,	the	
lipases	ATGL,	MGL	and	the	ATGL	co-activator	CGI-58,	increased	significantly	after	sixteen	weeks	
of	exercise	training	(p<0.05;	Figure	4.2C).	
	
Figure	4.2:	Gene	expression	targets	in	adipose	tissue	known	to	be	involved	in	lipid	droplet	
regulation	and	lipolysis	were	altered	at	16	weeks	of	exercise	training	in	the	women	with	
PCOS	(Exercise	training	intervention,	women	with	PCOS	only).	A)	Gene	expression	of	the	
perilipin	family	of	proteins	from	before	to	after	exercise	demonstrates	that	only	PLIN3	is	
significantly	elevated	following	exercise	training.	B)	Coatomer	gene	expression	reveals	that	
ARF1,	ARFRP1,	βCOP,	which	were	grossly	decreased	when	compared	to	controls	before	exercise	
training,	revealed	an	increase	in	their	expression.	Sec23a	was	also	increased	following	exercise	
training.	C)	Gene	expression	of	ATGL	and	MGL,	which	was	blunted	when	compared	to	controls	
at	baseline,	increased	with	exercise	training.	Additionally,	CGI-58	increased	following	exercise	
training.	*p	<	0.05	
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4.3.3	Primary	Adipose	Culture	Lipid	Droplet	Morphology	and	Lipolysis	
As	shown	in	Figure	4.3,	primary	adipocyte	cultures	revealed	larger	lipid	droplet	
morphology	in	women	with	PCOS	compared	to	control,	which	decreased	in	size	after	exercise	
training,	and	thus	more	closely	resembled	the	morphology	of	control	females	(Figure	4.3).	In	
vitro	measures	of	fat	oxidation	and	lipolysis	in	primary	cultured	adipocytes	showed	that	oleate	
oxidation	and	glycerol	release	were	increased	following	exercise	training	(p<0.05,	Figure	4.4A	
and	4.4B).	Likewise,	total	triglyceride	content	was	reduced	after	exercise	(p<0.05,	Figure	4.4C).	
Since	PLIN3	was	the	only	perilipin	to	significantly	increase	in	adipose	tissue	on	the	mRNA	level,	
we	measured	the	protein	level	of	PLIN3	in	primary	adipose	culture.	We	found	virtually		
	
Figure	4.3:	Representative	images	of	stromal	derived	pre-adipocytes	cultured	and	
differentiated	into	adipocytes.	Women	with	PCOS	possessed	large	lipid	droplets	when	
compared	to	control	donors	matched	by	age,	BMI,	and	%	fat.	Lipid	droplet	morphology	
appeared	to	resemble	that	of	controls	in	our	cross-sectional	study	following	16	weeks	of	
aerobic	exercise	training	in	women	with	PCOS.	Bodipy	494	(Green)	was	used	to	identify	lipid	
and	DAPI	(Blue)	to	identify	nuclei.	
	
nonexistent	levels	of	PLIN3	in	4	out	of	5	women	with	PCOS,	while	the	expression	of	PLIN3	was	
present	in	controls	(Figure	4.4D).	Exercise	induced	protein	expression	of	PLIN3	in	those	4	
women	with	PCOS,	who	had	no	protein	expression	of	PLIN3	before	exercise,	and	was	increased	
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compared	to	pre-exercise	expression	in	the	one	woman	with	PCOS,	who	had	PLIN3	protein	
expression	present	before	exercise	training	(Figure	4.4D).		
	
Figure	4.4:	Ex	vivo	oleate	oxidation	studies	in	stromal	derived	adipose	cultures	from	women	
with	PCOS	and	PLIN3	protein	content.	Ex	vivo	oleate	oxidation	studies	revealed	that	stromal	
derived	adipose	cultures	from	women	with	PCOS	had	increased	completed	oleate	oxidation	as	
measured	by	14C	labeled	CO2	(A)	after	16	weeks	of	exercise	training.	Furthermore,	glycerol	
release	into	the	culture	media	was	increased	(B)	and	total	triglyceride	content	was	reduced	(C)	
in	the	adipose	cultures	of	women	with	PCOS	after	exercise	training.	D)	Both	cross-sectional	and	
exercise	intervention	expression	of	PLIN3,	the	only	perilipin	protein	to	increase	in	adipose	
tissue	in	the	women	with	PCOS	following	exercise	training	on	the	gene	expression	level,	were	
found	to	be	virtually	nonexistent	in	4	out	of	the	5	females	with	PCOS	donors	when	compared	to	
controls	in	their	primary	adipocyte	cultures.	Likewise,	expression	levels	increased	in	all	5	
females	with	PCOS	after	exercise	training	in	their	primary	adipose	cultures.	*p	<	0.05	
	
4.4	Discussion	
Our	data	highlights	a	previously	unrecognized,	potential	role	of	perilipin	3	in	adipose	
tissue	lipolysis	in	women	with	PCOS.	We	show	for	the	first	time	that	the	expressions	of	PLIN3,	
along	with	PLIN1	and	PLIN5,	is	greatly	reduced	in	adipose	tissue	of	women	with	PCOS	when	
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compared	to	age-	and	body	composition-	and	metabolically-matched	females.	PLIN3	mRNA	
expression	is	increased—the	only	perilipin	protein	to	significantly	increase—following	16	weeks	
of	aerobic	exercise	training	in	women	with	PCOS.	Additionally,	stromal-derived	primary	adipose	
cultures	from	PCOS	women	revealed	that	virtually	no	PLIN3	protein	is	expressed	before	
exercise	training,	but	becomes	expressed	following	exercise	training	coupled	with	increases	in	
oleate	oxidation.	We	previously	reported	that	exercise	training	in	this	cohort	increased	adipose	
tissue	lipolysis	under	adrenergic	stimulation	[103].	Our	data	suggest	that	PLIN3	may	in	part	
contribute	to	enhanced	adipose	tissue	lipolytic	stimulation.		
The	exercise	benefits	associated	with	improving	the	symptomatology	of	PCOS	has	been	
thoroughly	investigated.	Studies	have	shown	improvements	for	women	with	PCOS	in	insulin	
resistance[98,	99,	114,	115],	serum	lipids[114,	116],	and	cardiovascular	disease	risk[98,	99,	114,	
117].	Additionally,	menstrual	cycle	improvements	have	been	shown	following	exercise	
intervention	in	women	with	PCOS[98,	114,	118].	Though	some	studies	show	reductions	in	body	
weight	with	exercise[98,	99,	114],	several	studies	have	shown	that	benefits	occur	without	
weight	loss[106,	115,	119]	and	suggest	that	exercise	for	PCOS	would	be	recommended	even	if	
weight	loss	were	not	achieved.	Our	study	showed	improvements	in	insulin	resistance	as	
measured	by	euglycemic-hyperinsulinemic	clamps	(Table	4.1)	and	improvements	in	menstrual	
function[106].	However,	despite	all	these	benefits	of	exercise,	few	studies	have	investigated	
molecular	targets	in	the	adipose	tissue	from	women	with	PCOS.	This	seems	important	given	the	
reported	defects	in	adipose	tissue	function	previously	shown	in	women	with	PCOS	(reviewed	in	
[86]).	We	previously	reported	that	16	weeks	of	aerobic	exercise	can	improve	basal	and	
catacholemine	stimulated	lipolysis	of	adipose	tissue[103].	A	prior	investigation	showed	a	single	
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nucleotide	polymorphism	found	in	women	with	PCOS	for	the	perilipin	gene[104],	indicating	a	
potential	for	defects	in	the	perilipin	family	of	proteins,	which	are	involved	in	lipolysis.	Here,	we	
have	investigated	targets	that	regulate	adipose	tissue	lipolysis,	with	an	emphasis	on	PLIN3	given	
the	upregulation	of	gene	expression	seen	in	the	adipose	tissue	with	exercise.		
Studies	centered	on	the	perilipin	family	of	proteins	have	focused	heavily	on	the	
involvement	of	PLIN1	in	the	regulation	of	lipolysis	in	adipose	tissue	(reviewed	in	[120])	via	a	
coupling	of	PLIN1	phosphorylation	and	ATGL	activation	[121,	122].	However,	the	possible	role	
of	PLIN3	regulation	in	adipose	lipolysis	has	been	for	the	most	part	overlooked.	Studies	have	
shown	PLIN3	to	be	highly	expressed	in	adipocytes	and	described	to	have	a	preference	for	PLIN3	
to	coat	smaller	lipid	droplets	[123].	Additionally,	studies	in	HeLa	cells	have	revealed	a	
colocalization	of	ATGL	to	PLIN3	coated	lipid	droplets	during	lipolytic	stimulus	[44,	47].	
Furthermore,	a	handful	of	studies	investigating	the	role	of	PLIN3	in	skeletal	muscle	lipolysis	
demonstrated	that	PLIN3	colocalizes	to	lipid	droplets	in	rats	during	epinephrine	and	muscle	
contractile	stimulation	[43,	45].	Work	from	our	group	has	recently	shown	that	PLIN3	expression	
is	upregulated	following	aerobic	exercise	in	skeletal	muscle,	upregulated	in	response	to	lipolytic	
stimulation	in	human	primary	skeletal	myotube	cultures,	and	is	positively	associated	with	both	
ex	vivo	skeletal	muscle	and	in	vivo	whole	body	fat	oxidation	[105].	Our	data	here,	using	both	in	
vivo	and	in	vitro	systems,	shows	that	the	association	between	PLIN3	and	lipolysis	is	evident	in	
the	adipose	tissue	of	women	with	PCOS,	indicating	PLIN3	as	a	potential	novel	mediator	of	
lipolysis.		
Our	data	also	highlights	previously	uninvestigated	coatomer	GTPases	that	might	
potentially	be	involved	in	mediating	lipolysis.	We	show	a	lower	expression	of	ARF1,	ARFRP1,	
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and	βCOP1	in	women	with	PCOS	compared	to	controls;	the	expression	of	these	targets	
increases	greatly	following	16	weeks	of	aerobic	exercise	training	in	the	women	with	PCOS.	Soni	
et	al.	showed	that	ATGL	was	delivered	to	PLIN3	coated	lipid	droplets:	a	phenomenon	that	was	
inhibited	when	either	treated	with	brefeldin	A,	a	compound	known	to	inhibit	ARF1,	or	when	
several	of	the	coatomer	GTPases,	such	as	ARF1,	Sec23a,	βCOP,	and	GBF1	were	knocked	down	
[47].	Studies	from	our	group	have	shown	that	ARF1,	Sec23a,	and	ARFRP1	increase	their	
expression	with	aerobic	exercise	in	skeletal	muscle	and	with	lipolytic	stimulation	in	primary	
skeletal	muscle	cultures	[105].	Finally,	Guo	et	al.	found	differential	expression	of	coatomer	
GTPases	with	regards	to	differences	in	lipid	droplet	morphology	[22].	Likewise,	we	show	that	
independent	of	differences	in	fat	cell	size,	women	with	PCOS	possess	larger	lipid	droplet	
morphology	when	compared	to	their	age	and	body	composition	matched	controls.	Lipid	droplet	
morphology	more	closely	resembled	control	females	following	16	weeks	of	aerobic	exercise	in	
the	women	with	PCOS.	Alterations	in	these	coatomer	GTPases	may	perhaps	be	involved	in	
regulating	lipolysis	not	only	as	a	mediator	of	lipase	delivery	to	lipid	droplets,	but	also	as	a	
regulator	of	lipid	droplet	morphology.	Further	functional	investigations	are	warranted	to	
determine	these	mechanisms.		
We	also	observed	reduced	mRNA	expression	of	lipases	(both	ATGL	and	MGL)	in	the	
adipose	tissue	of	women	with	PCOS,	compared	to	controls.	The	expression	of	lipases	increased	
with	exercise,	which	would	be	expected	given	the	increase	in	both	in	vivo	and	in	vitro	lipolysis.	
One	aspect	of	lipase	expression	that	remains	elusive	is	that	prior	investigations	have	shown	
that	testosterone	mediates	the	expression	of	lipases	[96,	97].	Our	data	shows	that	lipase	
expression	is	increased	following	exercise	training	with	no	decreases	in	circulating	
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concentrations	of	total	testosterone	or	free	androgen	index,	perhaps	indicating	that	aerobic	
exercise	can	increase	adipose	tissue	lipolysis	despite	altering	testosterone	expression.	
Furthermore,	we	speculate	that	the	increases	in	lipase	expression	we	observed	are	not	solely	
responsible	for	the	increased	lipolysis	following	exercise	training.	In	fact,	previous	reports	show	
that	lipases	do	not	act	alone	on	lipid	droplets	to	facilitate	lipolysis,	but	require	a	chaperone	
such	as	the	perilipin	proteins	(reviewed	in	[120])	or	certain	coatomer	GTPases	[47].		
We	recognize	that	our	results	and	conclusions	are	based	on	observational	data	and	
associations	between	increases	in	lipolysis,	and	expression	of	PLIN3	and	coatomer	GTPases	
following	exercise,	and	does	not	establish	causative	results.	However,	given	the	preponderance	
of	our	findings	and	data	presented	in	prior	investigations	from	our	group	and	others,	we	believe	
that	these	associations	are	novel	and	relevant	to	highlight	potentially	new,	unrecognized	
targets	that	may	in	part	mediate	adipose	tissue	lipolysis.	Additionally,	it	is	noted	that	we	only	
conducted	the	exercise	intervention	in	the	women	with	PCOS,	since	our	original	design	was	a	
prospective	exercise	intervention	study	for	the	women	with	PCOS.	Although	we	did	not	conduct	
an	exercise	intervention	in	our	control	group	since	the	cross-section	component	was	added	
later,	the	goal	of	the	study	involving	the	control	group	was	to	perform	the	same	set	of	state-of-
the-art	assessments	(clamp,	MRI,	fat	cell	size,	DXA)	and	to	obtain	a	control	group	matched	on	
the	basis	of	metabolic	phenotype.		The	cross-sectional	comparison	demonstrates	novel	and	
robust	differences	between	the	women	with	PCOS	and	controls	and	is	able	to	further	
demonstrate	that	exercise	in	women	with	PCOS	can	rescue	defects	in	lipolysis	to	levels	
observed	in	control	subjects.	Due	to	our	rigorous	study	design,	supervised	and	carefully	
monitored	exercise	interventions,	and	extensive	phenotyping	analyses	of	the	women	with	PCOS	
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before	and	after	their	exercise	intervention,	we	are	confident	that	we	were	adequately	able	to	
identify	the	upregulation	of	PLIN3	gene	expression	as	well	as	the	coatomer	GTPases,	thus	
demonstrating	their	potential	role	in	the	improvements	in	adipose	tissue	lipolysis	following	
exercise	training.	Further	investigations	would	be	necessary	to	understand	specific	mechanistic	
roles	of	PLIN3	in	adipose	tissue	lipolysis.		
In	conclusion,	based	on	prior	evidence	from	single	nucleotide	polymorphisms	in	the	
perilipin	gene	[104],	we	investigated	the	expression	of	the	perilipin	family	of	proteins	in	the	
adipose	tissue	from	women	with	PCOS,	and	have	shown	that	several	perilipin	proteins	are	
differentially	expressed	in	women	with	PCOS	verses	age-	and	body	composition-matched	
control	females.	We	have	also	shown	that	coatomer	GTPases	(ARF1,	Sec23a,	βCOP,	GBF1,	
ARFRP1)	are	differentially	expressed	in	women	with	PCOS.	Sixteen	weeks	of	aerobic	exercise	
training	significantly	increased	PLIN3	expression	as	well	as	coatomer	GTPases	(ARF1,	Sec23a,	
βCOP,	GBF1,	ARFRP1).	Stromal-derived	primary	adipose	cultures	showed	increases	in	in	vitro	
lipolysis,	oleate	oxidation,	and	reductions	in	triglyceride	content	following	exercise	training.	
Additionally,	adipose	cultures	revealed	virtually	no	PLIN3	protein	expression	before	exercise,	
which	was	then	increased/became	expressed	following	exercise	training.	Finally,	primary	
adipose	cultures	demonstrated	a	large	lipid	droplet	morphology,	which	was	altered	by	exercise	
training,	despite	the	fact	that	there	were	no	differences	in	fat	cell	size	from	adipose	tissue	
cross-sectionally.	These	data	highlights	previously	unrecognized	and	novel	potential	targets	
that	might	be	responsible	for	improving	exercise	mediated	lipolysis	in	the	adipose	tissue	of	
women	with	PCOS.		
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CHAPTER	5:	GENERAL	DISCUSSION	
The	overarching	themes	of	these	investigations	highlights	a	previously	unrecognized	
potential	of	perilipin	3	(PLIN3)	as	a	facilitator	of	lipid	oxidation	in	sedentary,	but	otherwise	
healthy	individuals,	individuals	with	type	2	diabetes	(T2D),	and	women	with	polycystic	ovary	
syndrome	(PCOS).	Additionally,	coatomer	gtp-ase	proteins	that	have	been	investigated	in	stable	
cell	lines	before,	have	now	for	the	first	time	been	measured	in	relation	to	lipolytic	stimulation	in	
human	skeletal	muscle	and	adipose	tissue.	As	discussed	earlier,	current	research	focus	in	this	
field	rests	heavily	on	other	perilipin	proteins,	namely	perilipin	1	(PLIN1)	in	the	adipose	tissue	as	
well	as	perilipin	2	(PLIN2)	and	perilipin	5	(PLIN5)	in	the	skeletal	muscle.	As	such	until	now,	the	
potential	of	PLIN3	to	serve	as	a	target	for	inducing	lipid	oxidation	in	individuals	with	T2D	has	
been	overlooked.	However,	the	research	provided	here	should	serve	as	a	catalyst	for	future	
investigations	into	the	therapeutic	opportunity	that	PLIN3	and	the	coatomer	gtp-ases	might	
have	to	offer	for	improving	lipid	metabolism	in	the	skeletal	muscle	of	individuals	with	T2D.		
The	data	presented	in	chapter	2,	which	was	originally	published	in	PLoS	ONE	in	2014,	
shows	that	in	primary	skeletal	muscle	myotubes	donated	from	sedentary,	healthy	males,	
epinephrine	treatment	as	well	as	treatment	with	the	pharmacologic	cocktail	of	palmitate,	
forskolin,	and	ionomycin	(PFI),	both	known	to	increase	lipolysis,	increased	the	expression	of	
PLIN3	protein	content.	Coatomer	gtp-ases,	ARF1,	ARFR1,	and	GBF1,	increased	in	protein	
content,	and	ARF1,	Sec23a,	and	GBF1,	increased	in	mRNA	expression	following	PFI	treatment.	
These	data	were	combined	with	a	clinical	trial	involving	20	healthy	male	participants,	who	
underwent	a	single	endurance	exercise	bout	expending	650kcal	of	energy	with	biopsies	taken	
before	and	immediately	after	exercise.	The	clinical	results	showed	an	increase	in	PLIN3	skeletal	
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muscle	protein	content	following	exercise	as	well	as	significant	increases	in	the	mRNA	levels	of	
ARF1,	GBF1,	and	Sec23a.	Changes	in	the	expression	of	PLIN3	were	significantly,	positively	
correlated	with	changes	in	both	whole	body	in	vivo	lipid	oxidation	and	skeletal	muscle	specific	
ex	vivo	palmitate	oxidation.	The	combined	results	of	these	study	show	that	PLIN3	levels	are	
increased	with	lipolytic	stimulation,	whether	they	be	pharmacologic	or	physiologic,	in	the	
skeletal	muscle	of	humans	both	on	the	in	vitro	and	in	vivo	levels.		
In	chapter	3,	utilizing	a	second	clinical	trial	involving	29	sedentary	males,	which	was	
originally	published	in	the	Journal	of	Clinical	Endocrinology	and	Metabolism	in	2015,	it	was	
found	that	under	resting	conditions,	skeletal	muscle	protein	levels	of	PLIN3	were	correlated	
with	increased	lipid	oxidation	on	both	the	whole-body	level	in	vivo	from	24-hr	respiratory	
quotient	and	with	ex	vivo	skeletal	muscle	tissue	specific	palmitate	oxidation.	This	evidence	
independently	reproduced	the	data	that	was	shown	in	chapter	2.	Utilizing	primary	skeletal	
muscle	myotube	cultures,	PLIN3	was	artificially	knocked	down	using	siRNA,	and	levels	of	lipid	
oxidation	were	drastically	reduced.	The	combination	of	these	data	from	both	chapters	2	and	3	
display	evidence	that	human	skeletal	muscle	PLIN3	is	involved	in	lipid	oxidation	that	is	
reproducible	from	two	separate,	independent	clinical	trials,	on	both	the	whole-body	and	tissue-
specific	levels,	and	that	artificial	knockdown	of	PLIN3	by	siRNA	in	primary	muscle	culture	
reduces	lipid	oxidation	in	vitro.		
The	remainder	of	chapter	3	highlighted	the	possibility	that	the	functions	of	PLIN3	
mediated	lipid	oxidation	is	a	phenomenon	seen	only	in	primary	muscle	culture	taken	from	
sedentary	healthy	donors	and	donors	with	T2D.	PFI	treatments	were	used	on	myotube	cultures	
from	donors	who	were	physically	active,	donors	who	were	sedentary	but	otherwise	healthy,	
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and	donors	with	T2D.	In	a	time-course	following	3	days	of	PFI	treatments,	PLIN3	protein	levels	
as	well	as	protein	levels	of	the	coatomer	gtp-ase	ARFRP1	increased	in	the	myotubes	from	
donors	who	were	healthy	and	sedentary	and	donors	with	T2D.	However,	myotubes	from	active	
donors	did	not	express	much	of	either	PLIN3	or	ARFRP1,	but	rather	expressed	increased	protein	
levels	of	PLIN5.	Further,	utilizing	the	pharmacologic	brefeldin	A,	a	drug	that	inhibits	the	action	
of	ARF1,	in	vitro	lipid	oxidation	levels	were	significantly	decreased	in	the	myotubes	from	both	
the	sedentary	individuals	and	the	individuals	with	T2D.	However,	brefeldin	A	did	not	have	a	
significant	impact	on	the	lipid	oxidations	levels	of	myotubes	from	physically	active	donors.	
These	results	reveal	the	potential	of	two	separate	metabolic	pathways	for	lipid	oxidation	of	
lipid	droplets	that	is	mediated	either	by	PLIN3	and	coatomer	gtp-ases	or	by	PLIN5.	With	the	
evidence	presented,	it	would	seem	at	this	point	that	individuals	with	T2D	are	more	dependent	
on	the	PLIN3	mediated	pathway,	which	would	suggest	that	further	investigations	into	PLIN3	
might	uncover	a	potential	therapeutic	agent	for	increasing	skeletal	muscle	lipid	oxidation	in	
T2D.		
Two	questions	remained	following	the	investigations	in	chapters	2	and	3.	First,	though	it	
was	shown	that	when	PLIN3	was	knocked	down	artificially	in	primary	skeletal	muscle	culture	
using	siRNA,	lipid	oxidation	levels	decreased,	does	such	a	knockdown	exist	in	nature	and	what	
effects	does	it	have	on	lipid	oxidation?	Furthermore,	all	the	investigations	heretofore	have	
looked	into	the	skeletal	muscle	expression	of	PLIN3	and	the	coatomer	gtp-ases;	but	what	about	
in	human	adipose	tissue?	In	order	to	answer	these	questions,	it	was	shown	in	chapter	4,	which	
was	originally	published	in	the	European	Journal	of	Endocrinology	in	2015,	that	women	with	
polycystic	ovary	syndrome,	an	illness	characterized	by	infertility,	hyperandrogenism,	and	insulin	
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resistance,	naturally	had	nonexistent	protein	levels	of	PLIN3	in	their	subcutaneous	adipose.	
Likewise,	mRNA	levels	of	other	key	coatmer	gtp-ases	were	significantly	different	when	
compared	to	age-	and	weight-matched	control	women	without	PCOS,	as	well	as	wide	variation	
in	lipid	droplet	morphology	in	primary	adipose	cultures.	The	women	with	PCOS	underwent	a	
16-week	aerobic	exercise	trial,	with	repeated	subcutaneous	adipose	biopsies	and	whole	body	
lipid	oxidation	measured.	Following	exercise	training,	PLIN3	protein	expression	was	evident	in	
the	adipose	tissue,	and	whole	body	lipid	oxidation	increased.	Furthermore,	mRNA	expression	
levels	of	coatomer	gtp-ases	ARF1,	ARFRP1,	bCOP1,	and	Sec23a	also	significantly	increased,	and	
lipid	droplet	morphology	in	primary	adipose	cultures	resembled	that	of	the	control	women	
from	the	beginning	of	the	trial.	These	data	show	that	PLIN3	mediated	lipid	oxidation	potentially	
occurs	in	adipose	tissue	following	aerobic	exercise	and	that	a	naturally	occurring	knockdown	of	
PLIN3	is	associated	with	reduced	levels	of	lipid	oxidation.		
Continued	research	would	be	needed	to	understand	the	alterations	and	mechanisms	
between	the	PLIN3	mediated	lipid	oxidation	pathway	that	is	seen	in	sedentary	and	T2D	
individuals	and	the	PLIN5	mediated	lipid	oxidation	pathway	seen	in	active	individuals.	
Importantly,	the	results	presented	here	are	shown	only	on	the	in	vitro	level	in	primary	muscle	
cultures.	Regardless	of	how	robust	a	model	of	primary	tissue	culture	might	be,	it	is	important	to	
see	if	these	same	results	are	translatable	to	the	in	vivo	skeletal	muscle	tissue	in	individuals	with	
T2D.	Additionally,	continued	research	into	the	adipose	tissue	of	women	with	PCOS	concerning	
PLIN3	mediated	lipid	oxidation	might	also	help	to	improve	metabolic	outcomes	of	this	insulin	
resistant	disease.		
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	 Further	research	could	also	be	extended	to	identifying	transcription	factors	that	would	
regulate	the	increase	in	expression	of	PLIN3,	and	the	testing	of	pharmacologic	agonists	of	such	
transcription	factors.	As	described	in	the	introductory	chapters,	the	transcription	factors	that	
control	PLIN3	have	not	been	described.	However,	if	pharmacologics	could	be	targeted	to	
increase	its	expression,	more	clinical	investigations	could	be	utilized	to	provide	therapeutic	
benefit	of	patients	with	T2D.		
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